Chrono-optimal treatments for human immunodeficiency virus/hepatitis C virus co-infection yield comparable survival outcomes with hepatitis C virus mono-infection

Figure 1 Flow diagram of patient selection for the study. HBV: Hepatitis B virus; HCC: Hepatocellular carcinoma; HCV: Hepatitis C virus; HIV: Human immunodeficiency virus; SVR: Sustained virologic response.

Figure 2 Clinical outcomes in hepatitis C virus patients achieving sustained virologic response stratified by human immunodeficiency virus co-infection status. A and B: Kaplan-Meier estimates of overall survival (A) and time to the occurrence of hepatocellular carcinoma (B) in hepatitis C virus (HCV) patients who achieved sustained virologic response after treatment, stratified by human immunodeficiency virus co-infection status, after inverse probability of treatment weighting adjustment. Propensity scores of inverse probability of treatment weighting were computed using the age, sex, diabetes mellitus status, HCV treatment method, categorized scores for the fibrosis-4 index, the albumin-bilirubin score, and alpha-fetoprotein levels, presence of liver cirrhosis, Child-Pugh score, and HCV genotype. HCV: Hepatitis C virus; HIV: Human immunodeficiency virus.

Figure 3 Changes in the fibrosis-4 index in hepatitis C virus patients achieving sustained virologic response. A and B: Changes in the fibrosis-4 (FIB-4) index in hepatitis C virus mono-infected patients (A) and human immunodeficiency virus/hepatitis C virus co-infected patients (B) who achieved sustained virologic response after treatment. Within-patient changes in the FIB-4 index over time were assessed using repeated measures analysis of variance. The mean FIB-4 index is presented at the top of each bar in the graph. SVR: Sustained virologic response.